ID21861A - Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii - Google Patents

Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii

Info

Publication number
ID21861A
ID21861A IDW990105A ID990105A ID21861A ID 21861 A ID21861 A ID 21861A ID W990105 A IDW990105 A ID W990105A ID 990105 A ID990105 A ID 990105A ID 21861 A ID21861 A ID 21861A
Authority
ID
Indonesia
Prior art keywords
diabetes
treatment
type
resistance towards
towards insulin
Prior art date
Application number
IDW990105A
Other languages
English (en)
Inventor
Ertl Johann
Freibisch Gerald
Muller Gunter
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ID21861A publication Critical patent/ID21861A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IDW990105A 1996-09-20 1997-09-15 Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii ID21861A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20

Publications (1)

Publication Number Publication Date
ID21861A true ID21861A (id) 1999-08-05

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990105A ID21861A (id) 1996-09-20 1997-09-15 Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii

Country Status (18)

Country Link
US (1) US6399745B1 (id)
EP (1) EP0956302A1 (id)
JP (1) JP2001500869A (id)
KR (1) KR20010029537A (id)
CN (1) CN1230966A (id)
AR (1) AR008444A1 (id)
AU (1) AU735178B2 (id)
BR (1) BR9711513A (id)
CA (1) CA2266585A1 (id)
CZ (1) CZ90999A3 (id)
HU (1) HUP9904023A3 (id)
ID (1) ID21861A (id)
IL (1) IL129057A0 (id)
NO (1) NO991186L (id)
PL (1) PL332458A1 (id)
RU (1) RU2201249C2 (id)
WO (1) WO1998012224A1 (id)
ZA (1) ZA978455B (id)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP2392595A1 (en) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EA200870365A1 (ru) * 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
HUE042196T2 (hu) 2013-11-26 2019-06-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EA201990720A1 (ru) 2016-09-12 2019-08-30 Эгерион Фармасьютикалс, Инк. Способы детекции нейтрализующих антител к лептину
EP3675961A1 (en) * 2017-08-31 2020-07-08 University Of Dundee Leptin peptides and their use for treating neurological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
KR19990028388A (ko) * 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
PL332458A1 (en) 1999-09-13
ZA978455B (en) 1998-03-20
NO991186D0 (no) 1999-03-11
WO1998012224A1 (en) 1998-03-26
IL129057A0 (en) 2000-02-17
HUP9904023A2 (hu) 2000-03-28
NO991186L (no) 1999-03-11
US6399745B1 (en) 2002-06-04
BR9711513A (pt) 1999-08-24
AR008444A1 (es) 2000-01-19
JP2001500869A (ja) 2001-01-23
CA2266585A1 (en) 1998-03-26
HUP9904023A3 (en) 2002-01-28
RU2201249C2 (ru) 2003-03-27
AU4458697A (en) 1998-04-14
EP0956302A1 (en) 1999-11-17
KR20010029537A (ko) 2001-04-06
CN1230966A (zh) 1999-10-06
AU735178B2 (en) 2001-07-05
CZ90999A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
ID21861A (id) Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii
DK0833612T3 (da) Ny farmaceutisk sammensætning med bedøvende virkning
DK0758255T3 (da) Sprøjte med lav modstand
DE69726584D1 (de) Einmalspritze
DE59812316D1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt
FI955051A0 (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
DE69711561D1 (de) Vorgefüllte Spritze
BR9612678A (pt) Seringa descartável
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
EE200000161A (et) Halogeenasendatud tetratsüklilise tetrahüdrofuraani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
DE69522188D1 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
NO995831D0 (no) Injiserbar, klar formulering av et anestetisk middel
BR9502149A (pt) Seringa hipodérmica autodescartável
NO990097D0 (no) Ny behandling av leptin-resistens
FI971317A (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
EE200000712A (et) Eeltäidetud süstal ja selle kasutamine
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
NO995940D0 (no) Anvendelse av leptin antagonister for behandling av diabetes
SE9802518D0 (sv) Spruta med lösbar kanyl
BR7401733U (pt) Seringa travável descartável
ES1025589Y (es) Jeringuilla perfeccionada de un solo uso
FR2724114B1 (fr) Aiguille de seringue retro-ejectable
BR9601744A (pt) Seringa descartável aperfeiçoada
BR9604202A (pt) Seringa descartável de êmbolo-trava